STOCK TITAN
  1. Home
  2. News
  3. SOPH

SOPHiA Genetics SA - SOPH STOCK NEWS

Welcome to our dedicated news page for SOPHiA Genetics SA (Ticker: SOPH), a resource for investors and traders seeking the latest updates and insights on SOPHiA Genetics SA.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SOPHiA Genetics SA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SOPHiA Genetics SA's position in the market.

News
SOPHiA GENETICS Supports Genetic Testing in Brazil
Rhea-AI Summary
SOPHiA GENETICS (SOPH) announced a collaboration with Bioma4me, a Brazil-based company focused on genetic sequencing to drive precision medicine in Brazil. Bioma4me will use SOPHiA DDM™ Platform to advance and streamline its genetic testing capabilities, enabling fast turnaround time for results and full ownership over its data. Through this partnership, Bioma4me aims to advance the field of oncology, microbiome, and genetic diseases in Latin America.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.32%
Tags
none
-
News
SOPHiA GENETICS Enhances RareCyte Precision Biology Services Portfolio
Rhea-AI Summary
RareCyte Inc. has partnered with SOPHiA GENETICS to implement the SOPHiA DDM™ Platform for its Precision Biology Services portfolio. This partnership will enable RareCyte to provide DNA sequencing of circulating tumor cells and cell-free DNA for cancer patient testing, supporting the advancement of oncology, immuno-oncology, maternal-fetal health, and cell and gene therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.74%
Tags
none
-
News
SOPHiA GENETICS and Karkinos Healthcare Forge Strategic Partnership to Advance Cancer Research in India
Rhea-AI Summary
SOPHiA GENETICS partners with Karkinos Healthcare to advance cancer research and personalized cancer care in India. The partnership aims to expand access to precision oncology and equip local health institutions with the tools and technology needed to practice data-driven medicine. Karkinos Healthcare will use the SOPHiA DDM™ Platform to advance research and streamline workflow for a variety of blood cancers and solid tumors, with a focus on precision medicine for the underprivileged population of India.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
partnership
News
SOPHiA GENETICS Highlights Near-Term Growth Strategy at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
SOPHiA GENETICS (Nasdaq: SOPH) reports continued revenue growth driven by strong adoption and analysis volume of the SOPHiA DDM™ Platform. The company will present its near-term growth strategy at the 42nd annual J.P. Morgan Healthcare Conference, highlighting a record 315,000+ analyses globally in 2023, with over 1.5 million genomic profiles analyzed worldwide. New customer count for 2023 includes 87 core genomics customers globally, resulting in a current network of 750+ customers using SOPHiA DDM™ globally. The company also announced new U.S.-based customer Tennessee Oncology exploring MSK-ACCESS® powered with SOPHiA DDM™, Latin American healthcare network Dasa expanding to incorporate the liquid biopsy application, and The Royal Marsden live on the SOPHiA DDM™ Platform to support HRD testing and research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Exactis Innovation and SOPHiA GENETICS Announce Collaboration on Multimodal Data Analytics
Rhea-AI Summary
SOPHiA GENETICS (Nasdaq: SOPH) collaborates with Exactis Innovation, a non-profit network of hospital partners across Canada, to fuel cancer research and data-driven decision-making through the SOPHiA DDM™ platform. The collaboration aims to improve cancer survivorship in Canada by leveraging real-world data insights from multimodal datasets. The partnership will also enable Exactis to implement leading cancer testing solutions for its patient population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.58%
Tags
none
-
News
Hôpital Saint-Louis Implements SOPHiA DDM™ Platform to Further Research of Myeloid Disorders
Rhea-AI Summary
SOPHiA GENETICS (Nasdaq: SOPH) partners with Hôpital Saint-Louis in Paris to implement the SOPHiA DDM™ Platform for research on Myeloid Disorders, aiming to provide data-driven care to patients with MPNs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
SOPHiA GENETICS to Present at the J.P. Morgan 2024 Healthcare Conference
Rhea-AI Summary
SOPHiA GENETICS (NASDAQ: SOPH) CEO Jurgi Camblong, PhD., to present at J.P. Morgan 2024 Healthcare Conference on January 11, 2024, in San Francisco.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.17%
Tags
conferences
-
News
SOPHiA GENETICS Announces Expanded Suite of Liquid Biopsy Offerings
Rhea-AI Summary
SOPHiA GENETICS (Nasdaq: SOPH) expands its suite of solutions under SOPHiA DDM™ for Liquid Biopsy, offering MSK-ACCESS® powered with SOPHiA DDM™ and custom solutions to advance oncology research and tumor mutation profiling. Liquid biopsy testing provides an alternative to solid tumor testing by isolating cell-free DNA from blood plasma, allowing for faster, less invasive clinical decisions and simplified monitoring. The company's proprietary unique molecular identifier technology (CUMIN™) promises exceptional performance and reliable results in analyzing cell-free DNA samples.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.12%
Tags
none
-
News
SOPHiA GENETICS Announces Expansion of Work with CHU de Nîmes
Rhea-AI Summary
SOPHiA GENETICS (Nasdaq: SOPH) announces expanded research partnership with CHU de Nîmes, a regional and university hospital in France. CHU de Nîmes will utilize SOPHiA DDM™ Platform for pharmacogenomics research, aiming to personalize medication response based on genetic profiles.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.19%
Tags
none
News
SOPHiA GENETICS Expands Relationship with Città della Salute e della Scienza di Torino
Rhea-AI Summary
SOPHiA GENETICS (SOPH) expands its relationship with Città della Salute e della Scienza di Torino, the largest health center in Italy, to further utilize the SOPHiA DDM™ Platform on Microsoft Azure for research on homologous recombination repair (HRR) biomarkers. The cloud-native software company aims to support the hospital's research in various cancer types and rare diseases, revolutionizing data-driven medicine capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.31%
Tags
none
Stock SOPH logo
SOPHiA Genetics SA

Nasdaq:SOPH

SOPH Rankings

#3343 Ranked by Market Cap
#276 Ranked by Stock Gains
N/A Ranked by Dividends

SOPH Stock Data

326.51M
46.15M
5.92%
49.96%
0.08%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Switzerland
Rolle

About SOPH

sophia genetics, world's largest clinical genomics community, brings together expertise in genetics, bioinformatics, machine learning and genomic privacy. based in switzerland, we are known for our high medical standards and swiss precision. sophia genetics offers health professionals who perform clinical genetic testing unparalleled bioinformatics analysis, quality assurance and secure banking of patient dna sequence data generated by ngs. the company helps clinical laboratories to reduce costs, overcome complexity, significantly improve the turnaround time for routine diagnosis and meet quality requirements related to the use of ngs in the clinic. our solution, the sophia ddm™ platform allows hospitals to better and faster diagnose patients using cutting edge ngs analytics algorithms and through knowledge sharing within the largest clinical genomics community in the world (+100 hospitals). the name « sophia » means wisdom in greek and it is the definition of our excellence based